| P2093 | author name string | Belinda Jim | |
| | Pitchaphon Nissaisorakarn | |
| | Sairah Sharif | |
| P2860 | cites work | Comprehensive maternal serum proteomic profiles of preclinical and clinical preeclampsia | Q84455834 |
| | Hypertensive disorders in pregnancy: screening by uterine artery Doppler imaging and blood pressure at 11-13 weeks | Q84718035 |
| | Placental protein-13 and pregnancy-associated plasma protein-A as first trimester screening markers for hypertensive disorders and small for gestational age outcomes | Q84719535 |
| | Angiogenic biomarkers for prediction of maternal and neonatal complications in suspected preeclampsia | Q84724037 |
| | The classification, diagnosis and management of the hypertensive disorders of pregnancy: A revised statement from the ISSHP | Q85446003 |
| | The six stages of pre-eclampsia | Q85446689 |
| | Endoglin is an accessory protein that interacts with the signaling receptor complex of multiple members of the transforming growth factor-beta superfamily | Q22008597 |
| | Antihypertensive drug therapy for mild to moderate hypertension during pregnancy | Q24246376 |
| | Podocyturia predates proteinuria and clinical features of preeclampsia: longitudinal prospective study | Q24597867 |
| | Early Pregnancy Biomarkers in Pre-Eclampsia: A Systematic Review and Meta-Analysis | Q26781355 |
| | Accuracy of circulating placental growth factor, vascular endothelial growth factor, soluble fms-like tyrosine kinase 1 and soluble endoglin in the prediction of pre-eclampsia: a systematic review and meta-analysis | Q26825271 |
| | Endoglin regulates mural cell adhesion in the circulatory system | Q27326704 |
| | Soluble endoglin contributes to the pathogenesis of preeclampsia | Q28244053 |
| | Functional analyses of placental protein 13/galectin-13 | Q28249207 |
| | Glomerular expression of nephrin and synaptopodin, but not podocin, is decreased in kidney sections from women with preeclampsia | Q28285163 |
| | Novel biomarkers for predicting preeclampsia | Q28386182 |
| | A murine model of hereditary hemorrhagic telangiectasia | Q28592376 |
| | Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia | Q29615916 |
| | Use of uterine artery Doppler ultrasonography to predict pre-eclampsia and intrauterine growth restriction: a systematic review and bivariable meta-analysis | Q33323271 |
| | Circulating levels of copeptin, a novel biomarker in pre-eclampsia | Q33875627 |
| | A comparison of podocyturia, albuminuria and nephrinuria in predicting the development of preeclampsia: a prospective study | Q33882317 |
| | Can changes in angiogenic biomarkers between the first and second trimesters of pregnancy predict development of pre-eclampsia in a low-risk nulliparous patient population? | Q33923716 |
| | ACOG practice bulletin. Diagnosis and management of preeclampsia and eclampsia. Number 33, January 2002. | Q33990220 |
| | Vasopressin in preeclampsia: a novel very early human pregnancy biomarker and clinically relevant mouse model | Q34173305 |
| | The discovery of placenta growth factor and its biological activity. | Q34245619 |
| | Hypertension in pregnancy. Report of the American College of Obstetricians and Gynecologists’ Task Force on Hypertension in Pregnancy | Q34379583 |
| | Circulating microRNA expression profiles in pre-eclampsia: evidence of increased miR-885-5p levels. | Q34512770 |
| | Cell-free mRNA concentrations of CRH, PLAC1, and selectin-P are increased in the plasma of pregnant women with preeclampsia | Q34635362 |
| | First-trimester placental protein 13 screening for preeclampsia and intrauterine growth restriction | Q34647428 |
| | 2013 Practice guidelines for the management of arterial hypertension of the European Society of Hypertension (ESH) and the European Society of Cardiology (ESC): ESH/ESC Task Force for the Management of Arterial Hypertension | Q34656601 |
| | Glomerular-specific alterations of VEGF-A expression lead to distinct congenital and acquired renal diseases | Q34835409 |
| | Regulation of soluble fms-like tyrosine kinase-1 production in response to placental ischemia/hypoxia: role of angiotensin II. | Q35363716 |
| | Diagnostic accuracy of the soluble Fms-like tyrosine kinase-1/placental growth factor ratio for preeclampsia: a meta-analysis based on 20 studies | Q35567911 |
| | TGF-beta receptor function in the endothelium. | Q36017194 |
| | Priming and remodelling of human placental bed spiral arteries during pregnancy--a review | Q36100924 |
| | Vascular Endothelial Growth Factor (VEGF) and Its Receptor (VEGFR) Signaling in Angiogenesis: A Crucial Target for Anti- and Pro-Angiogenic Therapies | Q36137701 |
| | Podocyturia as a diagnostic marker for preeclampsia amongst high-risk pregnant patients | Q36205618 |
| | Circulating angiogenic factors in the pathogenesis and prediction of preeclampsia | Q36288766 |
| | Identification of patients at risk for early onset and/or severe preeclampsia with the use of uterine artery Doppler velocimetry and placental growth factor | Q36360704 |
| | Placental productions and expressions of soluble endoglin, soluble fms-like tyrosine kinase receptor-1, and placental growth factor in normal and preeclamptic pregnancies | Q36360771 |
| | Uterine artery Doppler in the prediction of adverse pregnancy outcome | Q36758150 |
| | Endoglin: a critical mediator of cardiovascular health | Q36825271 |
| | First-trimester prediction of preeclampsia using metabolomic biomarkers: a discovery phase study | Q37018001 |
| | Pathophysiology of hypertension during preeclampsia: linking placental ischemia with endothelial dysfunction | Q37022723 |
| | The SOMANZ Guidelines for the Management of Hypertensive Disorders of Pregnancy 2014 | Q57672198 |
| | Angiogenic factors combined with clinical risk factors to predict preterm pre-eclampsia in nulliparous women: a predictive test accuracy study | Q58035948 |
| | Free fetal DNA is not increased before 20 weeks in intrauterine growth restriction or pre-eclampsia | Q58825399 |
| | Maternal serum placental protein 13 at 11â 13 weeks of gestation in preeclampsia | Q61847857 |
| | Longitudinal Determination of Serum Placental Protein 13 during Development of Preeclampsia | Q61865449 |
| | Hypertension in pregnancy: clinical-pathological correlations and remote prognosis | Q70803180 |
| | Fall in mean arterial pressure and fetal growth restriction in pregnancy hypertension: a meta-analysis | Q73449672 |
| | First-trimester maternal serum PP-13, PAPP-A and second-trimester uterine artery Doppler pulsatility index as markers of pre-eclampsia | Q79409207 |
| | Predictive value of maternal angiogenic factors in second trimester pregnancies with abnormal uterine perfusion | Q79685499 |
| | Maternal serum sFlt1 concentration is an early and reliable predictive marker of preeclampsia | Q80496353 |
| | Increased urinary excretion of nephrin, podocalyxin, and βig-h3 in women with preeclampsia | Q83388487 |
| | Acute and transient podocyte loss and proteinuria in preeclampsia | Q83716971 |
| | Clinical characterization and outcomes of preeclampsia with normal angiogenic profile | Q37098433 |
| | Prediction and prevention of recurrent preeclampsia | Q37231387 |
| | Vascular biology of preeclampsia. | Q37352199 |
| | First-trimester maternal serum PP13 in the risk assessment for preeclampsia. | Q37444801 |
| | A comparison of the diagnostic utility of the sFlt-1/PlGF ratio versus PlGF alone for the detection of preeclampsia/HELLP syndrome | Q37642785 |
| | Immunology of pre-eclampsia | Q37717752 |
| | First trimester screening of maternal placental protein 13 for predicting preeclampsia and small for gestational age: in-house study and systematic review | Q38022895 |
| | A review of the mechanism for poor placentation in early-onset preeclampsia: the role of autophagy in trophoblast invasion and vascular remodeling | Q38130814 |
| | Pregnancy-associated plasma protein A (PAPP-A) and preeclampsia. | Q38208332 |
| | Role of placenta growth factor (PIGF) in human extravillous trophoblast proliferation, migration and invasiveness | Q38332375 |
| | Diagnosis, evaluation, and management of the hypertensive disorders of pregnancy | Q38535880 |
| | First trimester prediction of preeclampsia | Q38558882 |
| | Placental exosomes in normal and complicated pregnancy | Q38597290 |
| | Urinary proteomics for prediction of preeclampsia | Q39797354 |
| | Less-tight versus tight control of hypertension in pregnancy | Q41514274 |
| | Protein misfolding, congophilia, oligomerization, and defective amyloid processing in preeclampsia. | Q44381844 |
| | First-trimester metabolomic detection of late-onset preeclampsia | Q45328904 |
| | Prediction of early, intermediate and late pre-eclampsia from maternal factors, biophysical and biochemical markers at 11-13 weeks | Q46321423 |
| | Quantitative polymerase chain reaction-based analysis of podocyturia is a feasible diagnostic tool in preeclampsia | Q46322061 |
| | Trends in pregnancy hospitalizations that included a stroke in the United States from 1994 to 2007: reasons for concern? | Q46326993 |
| | Robust early pregnancy prediction of later preeclampsia using metabolomic biomarkers | Q46329980 |
| | Stroke and severe preeclampsia and eclampsia: a paradigm shift focusing on systolic blood pressure | Q46345137 |
| | Standardized treatment of 154 consecutive cases of eclampsia | Q46390147 |
| | Urinary congophilia in women with hypertensive disorders of pregnancy and preexisting proteinuria or hypertension | Q46664092 |
| | Maternal and neonatal copeptin levels at cesarean section and vaginal delivery | Q46817768 |
| | First-trimester maternal serum PAPP-A and free-beta subunit human chorionic gonadotropin concentrations and nuchal translucency are associated with obstetric complications: a population-based screening study (the FASTER Trial). | Q47860634 |
| | Early pregnancy levels of pregnancy-associated plasma protein a and the risk of intrauterine growth restriction, premature birth, preeclampsia, and stillbirth | Q47864591 |
| | First trimester maternal serum placental protein 13 for the prediction of pre-eclampsia in women with a priori high risk | Q47872838 |
| | Two-stage elevation of cell-free fetal DNA in maternal sera before onset of preeclampsia. | Q47889241 |
| | The role of trophoblast in the physiological change in decidual spiral arteries | Q48565186 |
| | Osmoregulation of thirst and vasopressin release in severe chronic renal failure | Q48875844 |
| | Screening for pre-eclampsia early in pregnancy: performance of a multivariable model combining clinical characteristics and biochemical markers. | Q50638104 |
| | Endoglin, PlGF and sFlt-1 as markers for predicting pre-eclampsia. | Q50779076 |
| | First trimester maternal serum pregnancy-associated plasma protein-A is a predictive factor for early preterm delivery in normotensive pregnancies. | Q51010638 |
| | Metabolomics and first-trimester prediction of early-onset preeclampsia. | Q51383635 |
| | First-trimester prediction of hypertensive disorders in pregnancy. | Q51775989 |
| | Sequential changes in antiangiogenic factors in early pregnancy and risk of developing preeclampsia. | Q51914188 |
| | Predictive Value of the sFlt-1:PlGF Ratio in Women with Suspected Preeclampsia. | Q52858097 |
| | Relationship between first-trimester serum placental protein-13 and maternal characteristics, placental Doppler studies and pregnancy outcome. | Q53165844 |
| | Urinary podocyte excretion as a marker for preeclampsia. | Q53562117 |
| | Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. | Q53600812 |
| | Temporal relationships between hormonal and hemodynamic changes in early human pregnancy. | Q54112770 |
| | Pregnancy-associated plasma protein A: Circulating levels during normal pregnancy | Q54332016 |
| | First-trimester serum soluble fms-like tyrosine kinase-1, free vascular endothelial growth factor, placental growth factor and uterine artery Doppler in preeclampsia. | Q54439388 |
| | Longitudinal evaluation of predictive value for preeclampsia of circulating angiogenic factors through pregnancy. | Q54483574 |
| | Performance of messenger RNAs circulating in maternal blood in the prediction of preeclampsia at 10-14 weeks. | Q54644655 |
| P433 | issue | 12 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | biomarker | Q864574 |
| | pre-eclampsia | Q61335 |
| P304 | page(s) | 131 | |
| P577 | publication date | 2016-12-01 | |
| P1433 | published in | Current cardiology reports | Q26842345 |
| P1476 | title | Hypertension in Pregnancy: Defining Blood Pressure Goals and the Value of Biomarkers for Preeclampsia | |
| P478 | volume | 18 | |